Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial

Author:

Kong Yee Wen12ORCID,Yuan Cheng Yi12,Kiburg Katerina12,Brown Katrin12,Trawley Steven134,Partovi Andi5,Roem Kerryn1,Pham Cecilia467,Harrison Natalie8,Fourlanos Spiros479,Ekinci Elif I467,O’Neal David N1247ORCID

Affiliation:

1. Diabetes Technology Research Group, The University of Melbourne , Melbourne, Victoria 3065 , Australia

2. Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne , Melbourne, Victoria 3065 , Australia

3. Department of Psychology, Cairnmillar Institute , Camberwell, Victoria 3124 , Australia

4. Department of Medicine, The University of Melbourne , Melbourne, Victoria 3065 , Australia

5. Keylead Health , Melbourne, Victoria 3065 , Australia

6. Department of Endocrinology, Austin Health , Heidelberg, Victoria 3084 , Australia

7. The Australian Centre for Accelerating Diabetes Innovations (ACADI), The University of Melbourne , Melbourne, Victoria 3010 , Australia

8. Geelong Endocrinology and Diabetes , Geelong, Victoria 3220 , Australia

9. Department of Diabetes and Endocrinology, The Royal Melbourne Hospital , Melbourne, Victoria 3052 , Australia

Abstract

Abstract Context Omnipod DASH Insulin Management System is a tubeless insulin pump that overcomes the physical inconveniences of conventional tubed insulin pump therapy (IPT). Objective We compared treatment satisfaction with Omnipod DASH System to usual care (multiple daily injections [MDIs] or tubed IPT) in adults with type 1 diabetes using self-monitoring blood glucose (SMBG). Methods Adults with type 1 diabetes on MDI (n = 40) or IPT (n = 25) from 4 diabetes centers in Australia were randomly assigned in a 1:1 nonblinded manner to Omnipod DASH System (Omnipod group) or continue usual care (Usual Care group) for 12 weeks, followed by a further 12-week extension during which all participants used the device. The primary outcome was treatment satisfaction assessed by change in Diabetes Technology Questionnaire “current” (ΔDTQ-current) score at 12 weeks (study end). Secondary outcomes included ΔDTQ-current following extension and other participant-reported outcomes (PROs) measuring quality of life, burden of disease treatment, and glycemic and device-related outcomes at 12 weeks (study end) and 24 weeks (end extension). Results Treatment satisfaction improved more in the Omnipod group vs the Usual Care group (ΔDTQ-current score of 16.4 [21.2] vs 0.0 [12.8]; P < .001) at study end. Significantly greater improvements in other PROs and glycated hemoglobin A1c were also observed. Improvements in DTQ-current and other PROs comparing study end and end extension were similar. While percentage in time in range change from baseline did not differ at study end (−2.0 [12.7] %), it was significantly greater at end extension (5.6 [10.9] %; P = .016). Conclusion The Omnipod DASH System resulted in greater treatment satisfaction at 12 weeks in adults with type 1 diabetes using SMBG that was sustained after 24 weeks of device use without compromising sleep quality and fear of hypoglycemia. Improvements in glycemia were also observed.

Publisher

The Endocrine Society

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3